Cargando…

Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway

AIM: The aim of this study was to investigate the effect and underlying pathway of pyrroline-5-carboxylate reductase-2 (PYCR2) on colorectal cancer (CRC). METHODS: The Cancer Genome Atlas (TCGA) database was used to analyze PYCR2 expression levels and clinical information. Cell proliferation was eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Feng, Huang, Xiaoxia, Xuan, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429024/ https://www.ncbi.nlm.nih.gov/pubmed/34512817 http://dx.doi.org/10.1155/2021/9950663

Ejemplares similares

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway
por: Su, Wei, et al.
Publicado: (2022)

IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways
por: Duan, Shiyu, et al.
Publicado: (2018)

Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway
por: Huang, Jie, et al.
Publicado: (2023)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

HRK inhibits colorectal cancer cells proliferation by suppressing the PI3K/AKT/mTOR pathway
por: Wang, Haowei, et al.
Publicado: (2022)

Functional properties and structural characterization of rice δ(1)-pyrroline-5-carboxylate reductase
por: Forlani, Giuseppe, et al.
Publicado: (2015)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
por: Edlind, Merritt P, et al.
Publicado: (2014)

EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling
por: Xu, Meng, et al.
Publicado: (2017)

LGR6 promotes the progression of gastric cancer through PI3K/AKT/mTOR pathway
por: Ke, Jing, et al.
Publicado: (2018)

Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress
por: Duan, Yi, et al.
Publicado: (2020)

LHPP suppresses gastric cancer progression via the PI3K/AKT/mTOR signaling pathway
por: Wang, Danfang, et al.
Publicado: (2022)

Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway
por: Feng, Guofei, et al.
Publicado: (2023)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway
por: Xie, Weiwei, et al.
Publicado: (2022)

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
por: Dong, Chao, et al.
Publicado: (2021)

ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression
por: Yang, Liqun, et al.
Publicado: (2023)

Naringin inhibits colorectal cancer cell growth by repressing the PI3K/AKT/mTOR signaling pathway
por: Cheng, Hongyun, et al.
Publicado: (2020)

Evolution of plant δ(1)-pyrroline-5-carboxylate reductases from phylogenetic and structural perspectives
por: Forlani, Giuseppe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cnnspk18pga2ob5t9sm8c1da0d